DocGo says short seller incorrect to claim dramatic decline in 2024 revenue

DocGo said it “categorically rejects this purported assessment by Fuzzy Panda Research, an obscure short seller motivated solely by profit.” The company added in a press release: “Several of the most glaring inaccuracies in the ‘report’ include: The claims made in the “ABC” liquidation in California are not liabilities of the Company and do not accurately reflect the former liabilities of the liquidated entity; In response to allegations about our billing practices, DocGo maintains a comprehensive internal compliance program (including the internal review of claims) and is routinely audited by outside agencies. We are very proud of our quality assurance and oversight; The ‘report’ incorrectly states that DocGo’s revenue is going to dramatically decline in 2024 due to the expiration of certain contracts with the City of New York when, in fact, DocGo is projecting an increase in revenue for fiscal year 2024 due to our multiple contracts with municipalities, healthcare systems and payors across the country and in the UK. We appreciate the continued support of our partners and investors and look forward to a bright future.”